Abstract: The present invention relates to an internal fixing device for an apparatus in a transport mode, an apparatus comprising said device, and a method for reducing the risk of damage to the apparatus during transport. The internal fixing device comprises a limiting device, eccentric roller transmission assemblies, a motor assembly, a motion guide assembly, etc. The two ends of a motor output shaft are fixedly disposed on eccentric roller transmission assemblies on two sides of the apparatus. By triggering a microswitch on the limiting device, eccentric rollers and rocking handles form self locking in a transport mode to stop motion. The present invention can effectively reduce the risk of damage to the apparatus during transport.

Abstract: Methods of reactivating latent human immunodeficiency virus (HIV) in one or more cells of a patient infected with HIV are provided. Methods of treating HIV infection and acquired immune deficiency syndrome (HIV/AIDS) in a patient are also provided. The methods can include administering a crotonylation-inducing agent to the patient. The methods can also include administering a crotonylation-inducing agent and one or more additional latency reversal agents (LRAs) to the patient. Pharmaceutical compositions including a crotonylation-inducing agent or pharmaceutical compositions including a crotonylation-inducing agent and one or more additional LRAs are also provided.

Abstract: Methods of reactivating latent human immunodeficiency virus (HIV) in one or more cells of a patient infected with HIV are provided. Methods of treating HIV infection and acquired immune deficiency syndrome (HIV/AIDS) in a patient are also provided. The methods can include administering a crotonylation-inducing agent to the patient. The methods can also include administering a crotonylation-inducing agent and one or more additional latency reversal agents (LRAs) to the patient. Pharmaceutical compositions including a crotonylation-inducing agent or pharmaceutical compositions including a crotonylation-inducing agent and one or more additional LRAs are also provided.

Abstract: The present invention provides compositions comprising ingenol-3-angelate (PEP005) and one or more additional latency reactivation agents. The present invention also provides methods for reactivating a latent virus in a subject infected with the virus, the method comprising administering to the subject an effective amount of ingenol-3-angelate (PEP005) alone or in combination with one or more additional latency reactivation agents. In particular embodiments, the combination of compounds advantageously provides a synergistic effect at inducing reactivation of a latent virus such as HIV.

Abstract: The present invention provides compositions comprising ingenol-3-angelate (PEP005) and one or more additional latency reactivation agents. The present invention also provides methods for reactivating a latent virus in a subject infected with the virus, the method comprising administering to the subject an effective amount of ingenol-3-angelate (PEP005) alone or in combination with one or more additional latency reactivation agents. In particular embodiments, the combination of compounds advantageously provides a synergistic effect at inducing reactivation of a latent virus such as HIV.

Abstract: The present invention provides compositions comprising ingenol-3-angelate (PEP005) and one or more additional latency reactivation agents. The present invention also provides methods for reactivating a latent virus in a subject infected with the virus, the method comprising administering to the subject an effective amount of ingenol-3-angelate (PEP005) alone or in combination with one or more additional latency reactivation agents. In particular embodiments, the combination of compounds advantageously provides a synergistic effect at inducing reactivation of a latent virus such as HIV.